This article is part of the supplement: The Third International Symposium on the Molecular Biology of Breast Cancer

Poster Presentation

Association of NCOA3 (AIB1) polymorphisms with breast cancer risk

B Burwinkel1, M Wirtenberger1, B Frank1, R Klaes2, RK Schmutzler3, E Grzybowska4, A Försti1,5, JL Bermejo1, P Bugert6, B Wappenschmidt3, D Butkiewicz4, J Pamula4, W Pekala4, H Zientek4, D Mielzynska7, E Siwinska7, CR Bartram2 and K Hemminki1,5

Author Affiliations

1 Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany

2 Institute of Human Genetics, University of Heidelberg, Germany

3 Department of Molecular Gynaeco-Oncology, Division of Gynaecology and Obstetrics, Clinical Center University of Cologne, Germany

4 Department of Tumor Biology, Center of Oncology, Maria Sklodowska-Curie Institute, Gliwice, Poland

5 Karolinska Institute, Department at Biosciences at Novum, Huddinge, Sweden

6 Institute of Transfusion Medicine and Immunology, Red Cross Blood Service of Baden–Württemberg–Hessia, University of Heidelberg, Faculty of Clinical Medicine, Mannheim, Germany

7 Department of Genetic Toxicology, Institute of Occupational Medicine and Environmental Health, Sosnowiec, Poland

For all author emails, please log on.

Breast Cancer Research 2005, 7(Suppl 2):P1.20 doi:10.1186/bcr1107


The electronic version of this article is the complete one and can be found online at:


Published:17 June 2005

©

Poster Presentation

The nuclear receptor coactivator 3 (NCOA3, also known as AIB1) is a coactivator of nuclear receptors like the estrogen receptor. NCOA3 is overexpressed in ~60% of primary human breast tumours, and high levels of NCOA3 expression are associated with tamoxifen resistance and worse survival rate. In contrast, NCOA3 deficiency suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Here we analysed the influence of NCOA3 coding single nucleotide polymorphisms on breast cancer risk by performing a case–control study using a German and a Polish study population, and identified an association between NCOA3 polymorphisms and breast cancer. A joint analysis of the German and Polish study population revealed a significant protective effect for the 1758G>C (Q586H) and 2880A>G (T960T) variants. In addition, haplotype analysis showed a protective effect of the 1758C-2880A and 1758G-2880G haplotypes (odds ratio = 0.79, 95% confidence interval = 0.67-0.93, P = 0.004). Due to the impact of NCOA3 in anti-estrogen therapy resistance, these polymorphisms might also influence therapy outcome in breast cancer.

Acknowledgements

BB and MW contributed equally to this work.